Wright Medical Technology Metal-on-Metal 522 Post-Market Surveillance Study
Status: | Enrolling by invitation |
---|---|
Conditions: | Arthritis, Arthritis, Chronic Pain, Osteoarthritis (OA), Orthopedic |
Therapuetic Areas: | Musculoskeletal, Rheumatology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 11/30/2018 |
Start Date: | April 11, 2018 |
End Date: | December 1, 2021 |
Post-Market Surveillance of the Wright Medical Technology Metal-on-Metal Total Hip System (FDA 522 Order)
This study is in response to the Food and Drug Administration (FDA) call to all manufacturers
with 510(k) clearance for metal-on-metal (MoM) total hip arthroplasty (THA) devices to
conduct postmarket surveillance studies. MicroPort has various acetabular shells, acetabular
liners, fixation screws, femoral heads, femoral stems, modular necks, and proximal bodies
currently cleared for MoM indications. Together these components comprise the Wright Medical
Technology (WMT) MoM THA System. The primary objective of the study is to determine the
incidence of adverse local tissue reactions (ALTR) in each THA implanted with the WMT MoM THA
System overall and for each yearly cross-section from 4-year to 8-year post implant.
with 510(k) clearance for metal-on-metal (MoM) total hip arthroplasty (THA) devices to
conduct postmarket surveillance studies. MicroPort has various acetabular shells, acetabular
liners, fixation screws, femoral heads, femoral stems, modular necks, and proximal bodies
currently cleared for MoM indications. Together these components comprise the Wright Medical
Technology (WMT) MoM THA System. The primary objective of the study is to determine the
incidence of adverse local tissue reactions (ALTR) in each THA implanted with the WMT MoM THA
System overall and for each yearly cross-section from 4-year to 8-year post implant.
Inclusion Criteria:
To be included in Group 1, subjects must meet all of the following criteria:
1. Has been implanted with appropriate components of the WMT MOM THA System for at least
four years +/- six months (i.e., 3.5 years since implantation), but not longer than
eight years and six months (i.e., 8.5 years since implantation)
2. Has previously undergone primary THA for any of the following:
1. non-inflammatory degenerative joint disease including osteoarthritis, traumatic
arthritis, or avascular necrosis;
2. inflammatory degenerative joint disease including rheumatoid arthritis;
3. correction of functional deformity.
3. Is willing and able to complete required study visit(s) and assessments
4. Plans to be available for the required study visit
5. Is capable of providing sufficient blood for sampling according to blood draw
procedures
6. Is willing to sign the approved Informed Consent document
Previously implanted bilateral subjects can have both THAs enrolled in the study provided:
1) the specified combination of components were implanted in both, 2) all other aspects of
the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject
count specified in the Clinical Trial Agreement and protocol enrollment strategy, and 4)
the subject agrees to a second Informed Consent document and data collection specific to
the second THA. Enrollment and treatment of a previously unimplanted hip is not permitted
in this study.
To be included in Group 2, subjects must meet all of the following criteria:
1. Does not have a metal implant (total hip, total knee, spinal, etc.) with the exception
of dental implants
2. Is not an employee of the Investigator
3. Is willing and able to provide Informed Consent document
4. Is willing and able to attend the requested study visit(s) and assessments
5. Is capable of providing sufficient blood for sampling according to blood draw
procedures
Exclusion Criteria:
Subjects will be excluded from either study group if they meet any of the following
criteria:
1. Subject is currently enrolled in another clinical investigation which could affect the
endpoints of this protocol
2. Subject is unwilling or unable to sign the Informed Consent document
3. Subject has documented substance abuse issues
4. Subject has an emotional or neurological condition that would pre-empt their ability
or willingness to participate in the study
5. Subject is currently incarcerated or has impending incarceration
6. Group 1 only: Subject has a condition or previously implanted medical device that
contraindicates MRI (e.g. pacemaker, implantable defibrillator)
7. Group 1 only: Subject was skeletally immature (less than 21 years of age) at time of
implantation
We found this trial at
4
sites
University of Iowa With just over 30,000 students, the University of Iowa is one of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials